Soluble Fas Ligand Inhibits Angiogenesis in Rheumatoid Arthritis
Author Information
Author(s): Kim Wan-Uk, Kwok Seung-Ki, Hong Kyung-Hee, Yoo Seung-Ah, Kong Jin-Sun, Choe Jongseon, Cho Chul-Soo
Primary Institution: Catholic University of Korea
Hypothesis
Does soluble Fas ligand (sFasL) induce synoviocyte apoptosis and regulate angiogenesis of endothelial cells in rheumatoid arthritis?
Conclusion
Soluble Fas ligand shows anti-angiogenic activity in rheumatoid arthritis by inducing apoptosis of VEGF165-producing cells and blocking VEGF165-induced migration of endothelial cells.
Supporting Evidence
- Levels of sFasL were higher in the synovial fluids of RA patients compared to OA patients.
- sFasL induced apoptosis in RA fibroblast-like synoviocytes in vitro.
- sFasL inhibited VEGF165-induced migration of endothelial cells.
- sFasL suppressed neovascularization in a Matrigel plug assay in vivo.
Takeaway
This study found that a substance called soluble Fas ligand can help stop the growth of new blood vessels in rheumatoid arthritis by killing certain cells and preventing other cells from moving.
Methodology
The study involved in vitro and in vivo experiments to assess the effects of sFasL on synoviocyte apoptosis and endothelial cell behavior.
Limitations
The study primarily focused on in vitro and animal models, which may not fully represent human conditions.
Participant Demographics
The study included 29 rheumatoid arthritis patients (9 females and 1 male) with a mean age of 48.3 years.
Statistical Information
P-Value
0.005
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website